KR940009528B1 - 헤테로 고리 화합물의 제조 방법 - Google Patents

헤테로 고리 화합물의 제조 방법 Download PDF

Info

Publication number
KR940009528B1
KR940009528B1 KR1019860007234A KR860007234A KR940009528B1 KR 940009528 B1 KR940009528 B1 KR 940009528B1 KR 1019860007234 A KR1019860007234 A KR 1019860007234A KR 860007234 A KR860007234 A KR 860007234A KR 940009528 B1 KR940009528 B1 KR 940009528B1
Authority
KR
South Korea
Prior art keywords
dihydro
thiadiazole
carboxylic acid
alanyl
oxopropyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1019860007234A
Other languages
English (en)
Korean (ko)
Other versions
KR870002107A (ko
Inventor
찰스 브라운 로저
헐름 로빈슨 데이비드
딕슨 존
Original Assignee
피존즈 피엘시
에프. 머피
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB858521697A external-priority patent/GB8521697D0/en
Priority claimed from GB858524932A external-priority patent/GB8524932D0/en
Priority claimed from GB858530143A external-priority patent/GB8530143D0/en
Priority claimed from GB868609793A external-priority patent/GB8609793D0/en
Priority claimed from GB868612060A external-priority patent/GB8612060D0/en
Application filed by 피존즈 피엘시, 에프. 머피 filed Critical 피존즈 피엘시
Priority claimed from SU874202059A external-priority patent/RU1804458C/ru
Publication of KR870002107A publication Critical patent/KR870002107A/ko
Application granted granted Critical
Publication of KR940009528B1 publication Critical patent/KR940009528B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/15—Six-membered rings
    • C07D285/16—Thiadiazines; Hydrogenated thiadiazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/022—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2
    • C07K5/0222—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2 with the first amino acid being heterocyclic, e.g. Pro, Trp
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Oscillators With Electromechanical Resonators (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1019860007234A 1985-08-31 1986-08-30 헤테로 고리 화합물의 제조 방법 Expired - Fee Related KR940009528B1 (ko)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
GB858521697A GB8521697D0 (en) 1985-08-31 1985-08-31 Nitrogen & sulphur heterocycles
GB85/21697 1985-08-31
GB858524932A GB8524932D0 (en) 1985-10-09 1985-10-09 Nitrogen & sulphur heterocycles
GB85/24932 1985-10-09
GB85/30143 1985-12-06
GB858530143A GB8530143D0 (en) 1985-12-06 1985-12-06 Nitrogen
GB868609793A GB8609793D0 (en) 1986-04-22 1986-04-22 Nitrogen containing heterocycles
GB86/09793 1986-04-22
GB86/12060 1986-05-17
GB868612060A GB8612060D0 (en) 1986-05-17 1986-05-17 Nitrogen containing heterocycles
SU874202059A RU1804458C (ru) 1985-08-31 1987-02-09 Способ получени производных 1,3,4-тиадиазол-2-карбоновых кислот или их фармацевтически приемлемых солей, сложных эфиров или амидов

Publications (2)

Publication Number Publication Date
KR870002107A KR870002107A (ko) 1987-03-30
KR940009528B1 true KR940009528B1 (ko) 1994-10-14

Family

ID=27546912

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019860007234A Expired - Fee Related KR940009528B1 (ko) 1985-08-31 1986-08-30 헤테로 고리 화합물의 제조 방법

Country Status (19)

Country Link
US (1) US4927822A (enExample)
EP (1) EP0217519B1 (enExample)
JP (1) JPH0788365B2 (enExample)
KR (1) KR940009528B1 (enExample)
AT (1) ATE72431T1 (enExample)
AU (1) AU591165B2 (enExample)
BE (1) BE905351A (enExample)
CA (1) CA1305286C (enExample)
CH (1) CH671397A5 (enExample)
DK (1) DK406386A (enExample)
FI (1) FI87205C (enExample)
FR (1) FR2586679B1 (enExample)
GR (1) GR862234B (enExample)
IE (1) IE59432B1 (enExample)
IL (1) IL79841A (enExample)
LU (1) LU86569A1 (enExample)
NO (1) NO166180C (enExample)
NZ (1) NZ217398A (enExample)
PT (1) PT83277B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT87616B (pt) * 1987-06-24 1992-09-30 Smithkline Beecham Corp Processo de preparacao de antagonistas do leucotrieno e de composicoes farmaceuticas
GB8825541D0 (en) * 1988-11-01 1988-12-07 Fisons Plc Formulation
WO1994020460A1 (en) * 1993-03-11 1994-09-15 Smithkline Beecham Corporation Chemical compounds
ATE480527T1 (de) * 2001-12-11 2010-09-15 Kyowa Hakko Kirin Co Ltd Thiadiazolinderivate zur krebsbehandlung
ES2394850T3 (es) 2003-04-18 2013-02-06 Kyowa Hakko Kirin Co., Ltd. Inhibidor de cinesina mitótica
KR20060014071A (ko) * 2003-06-10 2006-02-14 교와 핫꼬 고교 가부시끼가이샤 티아디아졸린 유도체
WO2004111023A1 (ja) * 2003-06-10 2004-12-23 Kyowa Hakko Kogyo Co., Ltd. チアジアゾリン－１－オキシド誘導体
US20070112044A1 (en) * 2003-10-10 2007-05-17 Kyowa Hakko Kogyo Co., Ltd. Thiadiazoline derivative
US7449486B2 (en) * 2004-10-19 2008-11-11 Array Biopharma Inc. Mitotic kinesin inhibitors and methods of use thereof
JPWO2006101103A1 (ja) * 2005-03-22 2008-09-04 協和醗酵工業株式会社 造血器腫瘍治療剤
TW200714593A (en) * 2005-03-22 2007-04-16 Kyowa Hakko Kogyo Kk Agent for treatment of solid tumor
UA95907C2 (en) 2005-05-02 2011-09-26 Эррей Биофарма Инк. Mitotic kinesin inhibitors and methods of use thereof
JPWO2006137490A1 (ja) 2005-06-24 2009-01-22 協和発酵キリン株式会社 再狭窄治療剤
DE102006002065B4 (de) * 2006-01-16 2007-11-29 Infineon Technologies Austria Ag Kompensationsbauelement mit reduziertem und einstellbarem Einschaltwiderstand
EP2057117A2 (en) 2006-08-21 2009-05-13 Synta Pharmaceuticals Corporation Compounds for treating proliferative disorders
EP2081918A2 (en) * 2006-10-03 2009-07-29 Array Biopharma, Inc. Mitotic kinesin inhibitors and methods of use thereof
EP2225201A2 (en) * 2007-11-28 2010-09-08 Synta Pharmaceuticals Corp. Polymorphs of n-malonyl-bis(n'-methyl-n'-thiobenzoylhydrazide)
TW200940050A (en) * 2007-11-28 2009-10-01 Synta Pharmaceuticals Corp Polymorphs of N-malonyl-bis(N'-methyl-N'-thiobenzoylhydrazide)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4198517A (en) * 1976-12-03 1980-04-15 E. R. Squibb & Sons, Inc. Histidine derivatives
US4091024A (en) 1976-12-03 1978-05-23 E. R. Squibb & Sons, Inc. Pyrrolidine and piperidine-2-carboxylic acid derivatives
IL58849A (en) 1978-12-11 1983-03-31 Merck & Co Inc Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them
US4254267A (en) * 1979-10-25 1981-03-03 E. R. Squibb & Sons, Inc. Mercaptoacyldihydropyrazole carboxylic acid derivatives
US4312990A (en) * 1980-09-11 1982-01-26 E. R. Squibb & Sons, Inc. 1-Mercaptoacyl-3-[(aminosulfonyl) phenyl]-4,5-dihydro-1H-pyrazole-5-carboxylic acid
GR75019B (enExample) * 1980-09-17 1984-07-12 Univ Miami

Also Published As

Publication number Publication date
NO863457D0 (no) 1986-08-28
EP0217519A1 (en) 1987-04-08
NO863457L (no) 1987-03-02
JPS6253976A (ja) 1987-03-09
PT83277B (pt) 1989-03-30
PT83277A (en) 1986-09-01
BE905351A (fr) 1987-03-02
LU86569A1 (fr) 1986-12-02
CH671397A5 (enExample) 1989-08-31
FR2586679B1 (fr) 1988-12-30
JPH0788365B2 (ja) 1995-09-27
ATE72431T1 (de) 1992-02-15
IE862322L (en) 1987-02-28
FI87205B (fi) 1992-08-31
EP0217519B1 (en) 1992-02-05
FI87205C (fi) 1992-12-10
AU591165B2 (en) 1989-11-30
IL79841A (en) 1992-02-16
CA1305286C (en) 1992-07-14
NO166180C (no) 1991-06-19
DK406386D0 (da) 1986-08-26
FI863488A0 (fi) 1986-08-28
IE59432B1 (en) 1994-02-23
US4927822A (en) 1990-05-22
FR2586679A1 (fr) 1987-03-06
KR870002107A (ko) 1987-03-30
AU6179886A (en) 1987-03-05
NZ217398A (en) 1989-04-26
DK406386A (da) 1987-03-01
NO166180B (no) 1991-03-04
GR862234B (en) 1986-12-31
IL79841A0 (en) 1986-11-30
FI863488A7 (fi) 1987-03-01

Similar Documents

Publication Publication Date Title
KR940009528B1 (ko) 헤테로 고리 화합물의 제조 방법
AU661616B2 (en) Benzo-fused lactams
US4634689A (en) Phosphinylalkanoyl imino acids
US4748160A (en) Angiotensin converting enzyme inhibitors and their formulation and use as pharmaceuticals
US4668797A (en) Bicyclic aminoacids as intermediates and processes for their preparation
KR910007968B1 (ko) 축합 7원 고리 화합물의 제조방법
JPH07196658A (ja) 縮合多環式ラクタム含有化合物
US5541209A (en) Method of treating or preventing cardiac arrhythmia employing an N-substituted heterocyclic derivative
US4508727A (en) Antihypertensive 2-oxo-imidazolidine derivatives
AU2008320718B2 (en) Indol-2-one derivatives disubstituted in the 3-position, preparation thereof and therapeutic use thereof
KR890001146B1 (ko) 아미도-아미노산 및 그의 제조 방법
US5434167A (en) Imidazolines N-substituted by a biphenylmethyl group, their medical use and the pharmaceutical compositions therefor
KR20110025970A (ko) 트롬빈 억제제로서 사용하기 위한 신규 복소환 카복스아미드
JPH0688989B2 (ja) アシルアミノオキソまたはヒドロキシ置換アルキルアミノチアジン類およびチアゼピン類
SE434836B (sv) Tiazolidinforeningar
FI89716C (fi) Foerfarande foer framstaellning av terapeutiskt aktiva prolinderivat
JPH0448800B2 (enExample)
NZ202232A (en) N-carboxyalkylproline-containing tripeptides and pharmaceutical compositions
JPS6115874A (ja) 抗高血圧剤及びコレシストキニンきつ抗物質として有用なベンゼン環の縮合したラクタム
GB2179655A (en) Angiotensin converting enzyme inhibiting compounds
JPS63275572A (ja) １，５−ベンゾチアゼピン誘導体
KR20020058077A (ko) 1,3,4-옥사디아졸린-2-온 유도체 및 그 유도체를 유효성분으로 하는 약제
EP0156455A2 (en) Condensed seven-membered ring compounds, their production and use
RU2050357C1 (ru) Производные 1,3,4-тиодиазол-2-карбоновых кислот
JPS584770A (ja) 抗高血圧剤としてのイソキノリンカルボン酸誘導体

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

G160 Decision to publish patent application
PG1605 Publication of application before grant of patent

St.27 status event code: A-2-2-Q10-Q13-nap-PG1605

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 19971015

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 19971015

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000